Aehr Test Systems Wins $41 Million AI Order, Hits All-Time High
NEW YORK, May 9 —
Aehr Test Systems, Inc. just won a $41 million AI order worth nearly its entire annual revenue, sending shares to a record $102.71.
- $41mn order win drove AEHR to an all-time high of $102.71; shares last at $97.23
- 648.2x fwd P/E on $45mn TTM revenue. The market is pricing a company several times larger than the one currently reporting.
- Next data point: order backlog size and revenue guidance at the next earnings report
What Actually Happened
At $41 million, this order is roughly 91% of Aehr's trailing twelve-month revenue of $45 million. That is not a routine contract win. It is a backlog event that forces a line-by-line rethink of forward estimates. Aehr builds wafer-level burn-in and test systems, a niche that sits directly upstream of chip assembly and becomes more critical as AI accelerators require tighter reliability tolerances at scale. Here is the angle the wire services skipped: Aehr's AI exposure is not through software, cloud, or chip design. It comes from the unglamorous physics of stress-testing silicon before it ever ships to a hyperscaler. When AI capital expenditure scales, wafer test volumes scale with it, and Aehr collects regardless of which chip architecture wins.
The Catch
A 648.2x forward P/E on $45mn in TTM revenue is not a valuation — it is a declaration of faith. The all-time high of $102.71 reflects momentum-driven buying as much as any analyst upgrade cycle. One $41mn order confirms Aehr's positioning in AI test infrastructure. It does not resolve the arithmetic. Revenue guidance at the next earnings call will determine whether this is the first win in a multi-year demand cycle or a lumpy single-quarter contract that leaves investors waiting for the pipeline to refill.
Bottom Line
Growth investors get a genuine AI infrastructure toll-road thesis here. Aehr does not need to pick the winning model, GPU, or cloud platform. For value investors, 648x on $45mn in annual revenue is simply not a conversation. The one number that changes this story at the next earnings call is order backlog. If it grows beyond this $41mn win, estimate revision momentum builds and the valuation starts to compress from the top down. If the pipeline stalls, the stock is running on narrative at a price that assumes it never will.
For a full breakdown of Aehr Test Systems' financials, competitive position, and valuation, generate a Basis Report at /stock/aehr.
Basis Report does not hold positions in securities discussed. This is not investment advice.